Thermo Fisher Scientific Gemtuzumab Recombinant Human Monoclonal Antibody (hP67.6 (Gemtuzumab))

Applications

Tested Dilution

Publications

Immunocytochemistry (ICC/IF)

Assay-dependent

-

Flow Cytometry (Flow)

Assay-dependent

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Human / IgG4, kappa

Expression System

HEK293 cells

Class

Recombinant Monoclonal

Type

Antibody

Clone

hP67.6 (Gemtuzumab)

Immunogen

Gemtuzumab was generated by huminization of the murine P67.6 clone, raised against CD33-transfected FMY9S5 cells of human origin. CD33 is a transmembrane receptor expressed on predominantly on cells of the myeloid lineage, but it can also be found on some lymphoid cells.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1 mg/mL

Purification

Protein A

Storage buffer

PBS

Contains

0.02% ProClin 300

Storage conditions

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

Shipping conditions

Wet ice

Product Specific Information

Recognises human CD33.

Target Information

Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibodyLabel. The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.